Blockchain Registration Transaction Record

Soligenix Secures Funding Through 2026 for Pipeline Advancement

Soligenix strengthens financial position with $7.5M offering, extending cash runway through 2026 to advance rare disease and biodefense pipeline with multiple catalysts ahead.

This financial stability enables Soligenix to focus entirely on advancing its rare disease and biodefense programs without funding distractions, potentially accelerating the development of treatments for conditions with limited therapeutic options. For investors, it reduces execution risk and provides clear visibility into the company's ability to reach critical milestones through 2026. For patients, it means increased likelihood that promising therapies in development will progress through clinical trials toward potential regulatory approval and market availability.